Geneos Wealth Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Geneos Wealth Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200	Closed	-$26K	–	3033
2021 Q4	$26K	Hold	200	–	–	﹤0.01%	1754
2021 Q3	$25K	Hold	200	–	–	﹤0.01%	1814
2021 Q2	$24K	Hold	200	–	–	﹤0.01%	1832
2021 Q1	$22K	Hold	200	–	–	﹤0.01%	2045
2020 Q4	$24K	Hold	200	–	–	﹤0.01%	1811
2020 Q3	$15K	Hold	200	–	–	﹤0.01%	1807
2020 Q2	$21K	Buy	200 +100	+100%	+$8.69K	﹤0.01%	1608
2020 Q1	$7K	Buy	+100	New	+$8.55K	﹤0.01%	1963

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Geneos Wealth Management's KRTX Position: Q1 2022 in Review

Geneos Wealth Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2022, closing a stake of 200 shares — an estimated $26K sold.

Geneos Wealth Management first reported a position in KRTX in Q1 2020 and held it in 8 quarters. The position peaked at $26K in Q4 2021. 177 funds tracked by Wall St. Rank hold KRTX as of Q1 2022.

Geneos Wealth Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Geneos Wealth Management sold 200 Karuna Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $26K.
Geneos Wealth Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 8 quarters.
Geneos Wealth Management's Karuna Therapeutics, Inc. Common Stock position peaked at $26K in Q4 2021.
177 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Geneos Wealth Management's 13F filing for Q1 2022, filed 16 May 2022.